Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease.
Today, we announced our participation at two upcoming investor conferences! Learn more about our upcoming presentations in our latest press release here: https://t.co/p0nsbxdwOU
Today, we released our second quarter 2025 financial results along with recent business updates. Learn more in the full news release here: https://t.co/vsNTdCKxYG
Today, we celebrate 10 years of incredible science, dedication, and teamwork! We couldn't have reached this milestone without our amazing employees, the physicians at our clinical trial sites, and the patients and their caregivers. Thank you for your passion and purpose!
Tomorrow, Kezar’s CEO, Chris Kirk, will participate in a fireside chat at the Jefferies Global Healthcare Conference! A webcast of the discussion will be available on our website's “Events & Presentations” section here: https://t.co/sGxpXGpbME
#JefferiesHealthcare
Today, we announced our participation in the Jefferies Global Healthcare Conference in #NewYorkCity next week. Learn more about our upcoming fireside chat in our latest press release here: https://t.co/yOPGoqJ0Ne
#JefferiesHealthcare
Today, we released our first quarter 2025 financial results along with recent business updates. Learn more in the full news release here: https://t.co/3ae3cmFKnk
Today, we released our second quarter 2024 financial results along with recent business updates. Learn more in the full news release here: https://t.co/EsouhNlgZe
We are excited to share that our partner, Everest Medicines, has dosed the first patient in China. Their team continues to integrate seamlessly with ours to drive forward our global Phase 2b clinical trial evaluating zetomipzomib in adults living with LN. https://t.co/6PvxWnIZaJ
Zetomipzomib is the only selective immunoproteasome inhibitor being evaluated in clinical trials for lupus nephritis. Learn more about the PALIZADE trial at https://t.co/PKVW5PASS1.
#PALIZADEtrial#zetomipzomib#LupusNephritis
Tomorrow, Kezar’s CEO Chris Kirk will participate in a fireside chat at the Jefferies Global Healthcare Conference! A webcast of the discussion will be available on our website's “Events & Presentations” section here: https://t.co/7SCSjUmVwX.
#Jefferies#Healthcare#LN
Lupus nephritis is a frequent and moderate-to-severe complication of lupus affecting the kidneys.
Learn about Kezar’s selective immunoproteasome inhibitor zetomipzomib being evaluated for those living with lupus nephritis: https://t.co/PKVW5PAl2t.
#LupusAwarenessMonth
Today, we announced our participation in the Jefferies Global Healthcare Conference in #NewYorkCity next week. Learn more about our upcoming fireside chat in our latest press release here: https://t.co/XjN52NMdJh
#Jefferies#Healthcare#Zetomipzomib
Today, we announced our first quarter 2024 financial results, including recent business updates. Learn more in the full news release here: https://t.co/bzEBuFLZ03
May is Lupus Awareness Month. Lupus is an autoimmune disease that causes chronic inflammation and organ damage. Lupus can affect anyone at any age and isn’t necessarily visible. Kezar invites you to promote lupus visibility by wearing purple this month!
#LAM#PutOnPurple